Organon FY2024 revenue $6.4B (+2%); guides FY2025 revenue $6.125-6.325B

Organon & Co.

2024-FY EPS reported $3.33 revenue$6,403,000,000

Full year 2024 revenue $6,401M (+2% as-reported, +3% constant currency); diluted EPS $3.33; non-GAAP adjusted diluted EPS $4.11.
Q4 revenue $1,592M flat YoY; net income $109M vs $546M (down 80%) due to prior-year one-time gain; adjusted net income $235M (+4%).
FY2025 guidance: revenue $6,125M-$6,325M (incl. ~$200M FX headwind); Adjusted EBITDA margin 31-32% (FY2024: 30.6%).
Biosimilars Q4 revenue down 18% on tender timing and U.S. pricing pressure; Women's Health flat as Nexplanon +12% offset NuvaRing decline.
Established Brands +2% driven by Emgality (Lilly license) and Vtama (Dermavant acquisition closed Oct 2024), partly offset by Atozet LOE.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.